8-K: Dynavax Acquired by Sanofi for $15.50/Share, Delists from Nasdaq

Dynavax Technologies Corporation has completed its merger with Sanofi, becoming an indirect wholly-owned subsidiary, with shares acquired at $15.50 per share.

Summary

• Dynavax Technologies Corporation completed its merger with Sanofi, a French socit anonyme, through its subsidiary Samba Merger Sub, Inc., on February 10, 2026.
• The tender offer to acquire all outstanding shares of Dynavax common stock for $15.50 per share in cash expired on February 9, 2026, with 84,680,752 shares tendered, representing approximately 73.92% of outstanding shares.
• Following the tender offer, Samba Merger Sub, Inc. merged into Dynavax, making Dynavax an indirect wholly-owned subsidiary of Sanofi.
• All outstanding Dynavax shares (excluding certain exceptions) were converted into the right to receive the $15.50 Offer Price.
• The company entered into First Supplemental Indentures for its 2.50% Convertible Senior Notes due 2026 (approximately $40.2 million outstanding) and 2.00% Convertible Senior Notes due 2030 ($225.0 million outstanding), changing the conversion right into cash based on the $15.50 Offer Price.
• All Company equity incentive plans, including the 2011, 2018, 2017, and 2021 Equity Incentive Plans and the 2014 Employee Stock Purchase Plan, were terminated.
• Outstanding options, restricted stock units (RSUs), and performance-based restricted stock units (PSUs) generally became fully vested and converted into cash payments based on the Merger Consideration.
• 50% of unvested equity awards granted in 2025 or 2026 were converted into cash-based awards, subject to original vesting terms and payment six months post-merger, with accelerated vesting upon involuntary termination.
• Dynavax notified Nasdaq to halt trading and delist its shares effective before the opening of trading on February 10, 2026, and intends to terminate its SEC registration and reporting obligations.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for Dynavax shareholders who tendered their shares, as it provides a clear cash exit at a predetermined price. The completion of the merger and the orderly transition of debt and equity obligations reflect a well-executed transaction, though it marks the end of Dynavax as an independent public entity.

Positives

• Shareholders who tendered their shares received a cash payment of $15.50 per share, providing liquidity and a defined return.
• Holders of convertible senior notes will have their conversion rights changed to cash based on the $15.50 Offer Price, ensuring a clear cash payout for their convertible debt.
• Most outstanding equity awards (options, RSUs, PSUs) became fully vested and converted into cash payments, benefiting employees and executives.
• Certain executives (Ryan Spencer, Kelly MacDonald, John Slebir) will receive excise tax reimbursement payments (gross-up payments) up to specified maximums, mitigating potential tax burdens from the merger.

Negatives

• Dynavax common stock will be delisted from the Nasdaq Global Select Market, removing its public trading presence.
• The company's SEC registration and reporting obligations will be terminated, reducing public transparency and access to financial information.
• All existing equity incentive plans and the employee stock purchase plan were terminated, ending future equity participation opportunities for employees under the previous structure.
• The company's independent board of directors resigned, and new directors and officers were appointed by the acquiring entity, signifying a complete change in corporate control and strategic direction.

Risks

• The filing does not explicitly mention future risks for the combined entity, as it primarily details the completion of the acquisition and its immediate effects. The risks associated with the merger itself would have been disclosed in prior filings.

Future Outlook

The filing indicates that Dynavax will cease to be a publicly traded company, with its shares delisted from Nasdaq and its SEC reporting obligations terminated. As a wholly-owned subsidiary of Sanofi, its future operations and strategic direction will be integrated into Sanofi's broader corporate strategy.

Management Comments

• The company entered into letter agreements with Ryan Spencer, Kelly MacDonald, and John Slebir to provide reimbursement for excise taxes that may be incurred on certain payments received in connection with the Merger, ensuring they are in the same net after-tax position as if no such excise tax had applied.

Industry Context

StockSavvy.ai notes that this acquisition reflects a continuing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Sanofi acquire smaller, innovative biotech firms to expand their product pipelines, gain access to new technologies, or eliminate competition. Such mergers often provide a premium for the acquired company's shareholders and integrate its assets into a more extensive global infrastructure.

Comparison to Industry Standards

• The acquisition price of $15.50 per share and the total valuation implied by the tender offer would typically be evaluated against recent M&A transactions in the biotech sector, considering factors like revenue multiples, pipeline value, and strategic fit. Without specific financial performance data for Dynavax in this filing, a direct comparison to peers like BioNTech's or Moderna's valuations at similar stages of growth or acquisition by larger players (e.g., Gilead's acquisition of Immunomedics) is not feasible from this document alone.
• The gross-up payments for executive excise taxes are a common, though sometimes controversial, feature in M&A deals, designed to ensure executives are not penalized by specific tax rules (Section 280G) related to change-of-control payments. This practice is consistent with many large corporate transactions in the U.S.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $15.50 per share in cash, providing a liquidity event and a defined return on their investment. The company's delisting means they no longer hold publicly traded shares.
• Convertible Note Holders: Their conversion rights were modified to a cash payout based on the $15.50 Offer Price, ensuring a clear and immediate financial outcome for their debt instruments.
• Employees: Most outstanding equity awards were converted to cash, providing immediate value. A portion of unvested awards converted to cash-based awards with continued vesting, offering retention incentives. Equity incentive plans were terminated, ending future equity participation under the previous structure.
• Management/Executives: Key executives received cash payouts for their equity awards and are eligible for excise tax reimbursements, mitigating potential tax liabilities from the change of control. New management appointments reflect the acquiring company's control.
• Customers/Suppliers: The filing does not directly address impacts on customers or suppliers, but the integration into Sanofi suggests potential changes in operational structure or product offerings over time.
• Regulatory Authorities: The company will cease to be an SEC reporting company, reducing its regulatory oversight requirements.

Next Steps

• Filing of Form 25 Notification of Removal from Listing and/or Registration with the SEC by Nasdaq to delist and deregister Dynavax shares.
• Filing of Form 15 Certification and Notice of Termination of Registration with the SEC by Dynavax to terminate registration and suspend reporting obligations under the Exchange Act.
• Payment of cash-based awards for 50% of unvested 2025/2026 equity awards six months following the merger closing date.

Key Dates

Keywords

Merger, Acquisition, Sanofi, Dynavax, Tender Offer, Delisting, Convertible Notes, Equity Awards, Corporate Governance, Change of Control, Biotechnology, Pharmaceuticals